The treatment period for babesiosis may extend to six weeks or more in severely immunocompromised patients, and cytochrome b (Cytb) and ribosomal protein subunit L4 (rpl4) mutations were associated with parasite resistance to ATO and AZI, respectively, resulting in treatment failure (Krause et al., 2008; Wormser et al., 2010; Vannier and Krause, 2012; Simon et al., 2017). This evidence concerns the gene MT-CYB and babesiosis.